In patients with upper-extremity CRPS 1, clinical parameters did not differ significantly between salmon calcitonin and paracetamol with shared physical therapy.
In plain wordsIn patients with CRPS 1, measured clinical outcomes did not differ significantly between salmon calcitonin and paracetamol with the same physical therapy.
- Peptide
- Calcitonin-salmon
- Outcome
- No significant changeClinical evaluation parameters
- Study
n = 35
- Comparator
- Paracetamol with shared physical therapy and exercise
- Outcome group
- Exercise and physical function · Musculoskeletal
- Studied dose
- 200 IU/day · 2 monthsAs given in this study (human).
Measurements
- P value
- > 0.05
- between groups
Source sentences
On the other hand, between the two groups there was no significant difference in any of the parameters (p>0.05)
4 context sentences(design, population, supporting numbers)
The evaluation parameters were: pain [visual analogue scale (VAS)], the angle of dorsiflexion (DF) and palmar flexion (PF) of the wrist, distance between the fingertip and distal palmar crease (FT-DPC), allodynia, hyperalgesia and trophic changes.
Patients who had suffered trauma to their upper extremities and developed CRPS 1 were included into this randomised, controlled single-blind study.
One group received paracetamol 1500 m/day and the other group salmon calcitonin 200 IU/day for 2 months.
All of the patients participated in a physical therapy and exercise programme.